Your browser is no longer supported. Please, upgrade your browser.
Cardiovascular Systems, Inc.
Index- P/E- EPS (ttm)-0.51 Insider Own3.10% Shs Outstand39.09M Perf Week-18.36%
Market Cap800.05M Forward P/E- EPS next Y-0.14 Insider Trans0.00% Shs Float38.84M Perf Month-48.13%
Income-20.00M PEG- EPS next Q-0.02 Inst Own95.20% Short Float2.49% Perf Quarter-47.43%
Sales256.80M P/S3.12 EPS this Y56.50% Inst Trans-1.71% Short Ratio3.57 Perf Half Y-51.13%
Book/sh6.73 P/B2.82 EPS next Y125.00% ROA-5.80% Target Price37.40 Perf Year-44.83%
Cash/sh4.46 P/C4.26 EPS next 5Y- ROE-7.40% 52W Range19.14 - 48.28 Perf YTD-56.60%
Dividend- P/FCF- EPS past 5Y27.50% ROI-4.20% 52W High-60.67% Beta0.96
Dividend %- Quick Ratio5.30 Sales past 5Y7.80% Gross Margin75.50% 52W Low-0.78% ATR1.61
Employees780 Current Ratio6.10 Sales Q/Q-3.50% Oper. Margin-7.10% RSI (14)20.29 Volatility7.59% 6.80%
OptionableYes Debt/Eq0.08 EPS Q/Q-310.80% Profit Margin-7.80% Rel Volume1.35 Prev Close19.73
ShortableYes LT Debt/Eq0.08 EarningsNov 09 BMO Payout- Avg Volume270.67K Price18.99
Recom2.30 SMA20-25.94% SMA50-37.61% SMA200-48.31% Volume365,246 Change-3.75%
Nov-17-21Downgrade Needham Buy → Hold
Nov-10-21Downgrade Guggenheim Buy → Neutral
May-25-21Initiated Barclays Equal Weight $43
Nov-05-20Reiterated Needham Buy $44 → $47
Jul-22-20Initiated Northland Capital Outperform $40
Jul-17-20Initiated Barclays Overweight
Jun-11-20Upgrade Needham Hold → Buy
Apr-07-20Initiated Oppenheimer Outperform $47
Oct-18-19Initiated Guggenheim Buy
Apr-11-19Downgrade BofA/Merrill Buy → Underperform $51 → $42
Aug-22-18Initiated Stifel Buy $45
Jun-27-18Upgrade BofA/Merrill Underperform → Buy
Dec-15-17Downgrade Needham Buy → Hold
Oct-26-17Reiterated Needham Buy $37 → $36
Sep-22-17Initiated Raymond James Mkt Perform
Jun-21-17Downgrade BofA/Merrill Neutral → Underperform
Jan-30-17Initiated Lake Street Buy $40
Jan-26-17Reiterated Needham Buy $27 → $32
Oct-07-16Resumed JMP Securities Mkt Outperform
Aug-22-16Upgrade Leerink Partners Mkt Perform → Outperform
Dec-03-21 08:46AM  
Nov-24-21 04:05PM  
Nov-15-21 10:51AM  
Nov-10-21 09:29AM  
Nov-09-21 02:00PM  
Nov-05-21 06:26AM  
Nov-04-21 01:00PM  
Nov-02-21 04:05PM  
Oct-17-21 10:01AM  
Oct-11-21 04:05PM  
Sep-30-21 09:33AM  
Sep-29-21 04:40PM  
Sep-22-21 09:10AM  
Sep-20-21 11:30AM  
Sep-11-21 08:54AM  
Sep-03-21 11:31AM  
Aug-31-21 09:57AM  
Aug-30-21 04:05PM  
Aug-06-21 02:39AM  
Aug-05-21 08:41AM  
Aug-04-21 11:31PM  
Jul-30-21 10:36AM  
Jul-28-21 03:03PM  
Jul-27-21 07:00AM  
Jul-15-21 02:48PM  
Jul-14-21 07:00AM  
Jun-23-21 02:43AM  
Jun-02-21 07:00AM  
Jun-01-21 07:00AM  
May-21-21 10:04AM  
May-20-21 04:00AM  
May-18-21 02:38AM  
May-11-21 10:59AM  
May-06-21 07:31PM  
May-03-21 04:05PM  
Apr-27-21 07:00AM  
Apr-15-21 07:00PM  
Apr-09-21 08:25AM  
Apr-08-21 07:00AM  
Apr-05-21 03:10AM  
Mar-24-21 07:00AM  
Mar-23-21 07:56AM  
Mar-22-21 09:00AM  
Mar-18-21 07:27AM  
Mar-17-21 07:00AM  
Mar-05-21 11:30AM  
Feb-14-21 01:32PM  
Feb-11-21 07:00AM  
Feb-09-21 09:56AM  
Feb-08-21 04:05PM  
Feb-04-21 01:34PM  
Feb-03-21 10:30PM  
Feb-02-21 10:22AM  
Feb-01-21 07:00AM  
Jan-27-21 05:00PM  
Jan-19-21 09:00AM  
Jan-18-21 04:05PM  
Jan-13-21 07:00AM  
Jan-04-21 04:05PM  
Dec-18-20 08:28PM  
Dec-04-20 11:31AM  
Nov-11-20 07:00AM  
Nov-06-20 08:46AM  
Nov-04-20 08:31PM  
Nov-03-20 10:08AM  
Oct-28-20 12:32PM  
Oct-21-20 07:00AM  
Oct-14-20 08:00AM  
Oct-12-20 01:00PM  
Oct-07-20 07:00AM  
Sep-15-20 10:01AM  
Sep-03-20 11:31AM  
Aug-20-20 04:05PM  
Aug-19-20 11:38AM  
Aug-17-20 02:55AM  
Aug-06-20 10:43AM  
Aug-05-20 01:31AM  
Aug-04-20 06:45PM  
Aug-03-20 12:48PM  
Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aronson Martha GoldbergDirectorMay 10Buy34.591,50051,8857,500May 11 08:04 AM
Robb Rhonda J.Chief Operating OfficerMay 10Buy34.671,00034,670146,044May 11 08:02 AM
Ward Scott R.Chairman and CEOMay 10Buy34.411,00034,410507,815May 11 08:03 AM
Points Jeffrey S.Chief Financial OfficerMay 10Buy34.201,00034,20082,177May 11 08:02 AM